Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.177.55ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
B.1.177.55ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-11502.5China
B.1.177.55ORF1abChan-ORF1abGTGTGATGTTGAWATGACATGGTC2441.671635316330R-13317.5China
B.1.177.55ORF1abHKU-ORF1bTGGGGYTTTACRGGTAACCT20451877818797F-7043.36Hong Kong
B.1.177.55ORF1abHKU-ORF1bAACRCGCTTAACAAAGCACTC2142.861890918889R-17655.9Hong Kong
B.1.177.55SYoung-STATACATGTCTCTGGGACCA20452176321782F-19121.1Singapore
B.1.177.55SYoung-SATCCAGCCTCTTATTATGTTAGAC2437.52187621853R-22070.7Singapore
B.1.177.55SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
B.1.177.55SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-22073.5China
B.1.177.55SWon-SCTACATGCACCAGCAACTGT20502311423133F-22142.8South Korea
B.1.177.55SWon-SCACCTGTGCCTGTTAAACCA20502321323194R-21965.9South Korea
B.1.177.55EWon-ETTCGGAAGAGACAGGTACGTT2147.622625926279F-22650South Korea
B.1.177.55EWon-ECACACAATCGATGCGCAGTA20502636526346R-19261.4South Korea
B.1.177.55ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-24645.6Germany
B.1.177.55ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.177.55EHuang-EACTTCTTTTTCTTGCTTTCGTGGT2437.52629526318F-25022.8China
B.1.177.55EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.1.177.55ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.177.55ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.177.55NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.177.55NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.177.55NNIH-TH_NCGTTTGGTGGACCCTCAGAT20552832028339F-22019.3Thailand
B.1.177.55NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-22126.5Thailand
B.1.177.55NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.177.55NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.177.55NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.55NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.55NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.177.55NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.177.55NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.177.55NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.55NCorman-NCACATTGGCACCCGCAATC1957.892870628724F-23131.5Germany
B.1.177.55NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-22527.5Germany
B.1.177.55NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
B.1.177.55NWon-NGTTGCGACTACGTGATGAGG20552884928830R-23088.1South Korea
B.1.177.55NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.55NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.177.55NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.177.55NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-20936.4Hong Kong
B.1.177.55NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.55NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-21867.4China
B.1.177.55NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.55NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.55ORF1abNIID WH-1 F501R913TTCGGATGCTCGAACTGCACC2157.14484504F-24908.9Japan
B.1.177.55ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-25657.5Japan
B.1.177.55ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-21969.5Japan
B.1.177.55ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.177.55ORF1abNIID WH-1 Seq F519R840ACCTCATGGTCATGTTATGG2045502521F-20812.9Japan
B.1.177.55ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-20165.2Japan
B.1.177.55SWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-23366.4Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used